Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
From Disease Assessment to Advanced Therapy: A Practical Framework for Atopic Dermatitis
Kristine Kucera, PA-C, MPAS, DHSc
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE
Beverly MK Biller, MD, FACP
Mark Gurnell, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.